Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06055764
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-28
First Post:
2023-09-12
Brief Title:
Role of FDG PETCT in Patients With Metastasis of Unknown Origin
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Role of FDG PETCT in Patients With Metastasis of Unknown Origin
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluatation of the role of F18FDG-PETCT in patients with metastases of unknown origin
Detailed Description:
Cancer of unknown primary origin CUP includes a cluster of heterogeneous tumors that have exceptional clinical features it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation The incidence of CUP ranges around 2 of all new cancer diagnoses
The work up list of CUP include a biopsy proven malignancy a detailed physical examination many laboratory radiological and endoscopy However these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients In this context positron-emission tomography PET combined with computed tomography PETCT using the radiotracer 18F fluoro- 2-deoxyglucose FDG is an alternative non-invasive imaging modality with accurate diagnostic performance It considered good tool for diagnosis of patients with CUP The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate
Failure to identify the primary tumor hampers optimization of management planning which in turn may adversely influence patient prognosis
The work up list of CUP include a biopsy proven malignancy a detailed physical examination many laboratory radiological and endoscopy However these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients In this context positron-emission tomography PET combined with computed tomography PETCT using the radiotracer 18F fluoro- 2-deoxyglucose FDG is an alternative non-invasive imaging modality with accurate diagnostic performance It considered good tool for diagnosis of patients with CUP The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate
Failure to identify the primary tumor hampers optimization of management planning which in turn may adversely influence patient prognosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None